Marissa Plescia / medcitynews - The DEA extended telemedicine prescribing flexibilities for controlled substances through the end of 2026, drawing praise from telehealth advocates who are urging a permanent solution.The post Advocates Applaud DEA’s Fourth Extension of Remote Prescribing…
AI Summary: The Drug Enforcement Administration has extended telemedicine prescribing flexibilities for controlled substances through 2026, maintaining the COVID-era approach. Telehealth advocates are cheering the move as it cements remote care as a long-term fixture, even as regulators and critics continue debating its broader safety implications.
Life-extending prostate cancer drug to be offered to thousands in England / 4 months
FDA Removes Warning Labels on Menopause Hormone Therapies / 6 months
AbbVie sues over Botox selection in Medicare price negotiations / 3 months
HHS drops 340B pilot following court rulings / 3 months
HHS scraps 340B rebate pilot following court rulls / 3 months
FTC settles insulin lawsuit forces Express Scripts policy changes / 3 months
Judge blocks 340B drug pricing pilot program implementation / 4 months
StackHealth RSS

StackHealth Time Machine
NorthFeed Inc. Terms and Conditions / Privacy Policy
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.